{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:41:06Z","timestamp":1794109266865,"version":"4.8.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01102-x","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T09:05:38Z","timestamp":1723021538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7908-0063","authenticated-orcid":false,"given":"J.","family":"Martinez-Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0090-6673","authenticated-orcid":false,"given":"N.","family":"Lopez-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0405-7480","authenticated-orcid":false,"given":"A.","family":"Chari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4144-0315","authenticated-orcid":false,"given":"S.","family":"Dorado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9133-9813","authenticated-orcid":false,"given":"T.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"1102_CR1","doi-asserted-by":"publisher","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","volume":"8","author":"B Diamond","year":"2021","unstructured":"Diamond B, Korde N, Lesokhin AM, Smith EL, Shah U, Mailankody S, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021;8:e422\u201332.","journal-title":"Lancet Haematol"},{"key":"1102_CR2","doi-asserted-by":"crossref","unstructured":"Paiva B, Garc\u00eda-Sanz R, San Miguel JF. Multiple myeloma minimal residual disease. En: Roccaro AM, Ghobrial IM, editores. Plasma Cell Dyscrasias [Internet]. Cham: Springer International Publishing; 2016 [citado 25 de octubre de 2023]. p. 103\u201322 (Cancer treatment and research, vol. 169). Disponible en: http:\/\/link.springer.com\/10.1007\/978-3-319-40320-5_7","DOI":"10.1007\/978-3-319-40320-5_7"},{"key":"1102_CR3","first-page":"584","volume":"40","author":"PY Yang","year":"2019","unstructured":"Yang PY, Liu MM, Fan HQ, Yang YP, Han W, Yu XY. et al. The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma. Zhonghua Xue Ye Xue Za Zhi Zhonghua Xueyexue Zazhi. 2019;40:584\u20138.","journal-title":"Zhonghua Xue Ye Xue Za Zhi Zhonghua Xueyexue Zazhi"},{"key":"1102_CR4","first-page":"2345","volume":"102","author":"GZ Yang","year":"2022","unstructured":"Yang GZ, Wang GR, Wang HJ, Zhang YR, Wu Y, Li YC. et al. The prognostic value of dynamic minimal residual disease after autologous hematopoietic stem cell transplantation in patients with multiple myeloma in novel-agent era. Zhonghua Yi Xue Za Zhi. 2022;102:2345\u201350.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"1102_CR5","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/bloodadvances.2020002037","volume":"4","author":"J Martinez-Lopez","year":"2020","unstructured":"Martinez-Lopez J, Wong SW, Shah N, Bahri N, Zhou K, Sheng Y, et al. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood Adv. 2020;4:3295\u2013301.","journal-title":"Blood Adv"},{"key":"1102_CR6","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1182\/blood.2023022080","volume":"143","author":"M D\u2019Agostino","year":"2024","unstructured":"D\u2019Agostino M, Bertuglia G, Rota-Scalabrini D, Belotti A, Mor\u00e8 S, Corradini P, et al. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma. Blood. 2024;143:592\u20136.","journal-title":"Blood"},{"key":"1102_CR7","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1158\/2326-6066.CIR-17-0012","volume":"5","author":"L Hansmann","year":"2017","unstructured":"Hansmann L, Han A, Penter L, Liedtke M, Davis MM. Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow. Cancer Immunol Res. 2017;5:744\u201354.","journal-title":"Cancer Immunol Res"},{"key":"1102_CR8","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"1102_CR9","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132:2456\u201364.","journal-title":"Blood"},{"key":"1102_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood.2022016782","volume":"141","author":"B Paiva","year":"2023","unstructured":"Paiva B, Manrique I, Dimopoulos MA, Gay F, Min CK, Zweegman S, et al. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials. Blood. 2023;141:579\u201391.","journal-title":"Blood"},{"key":"1102_CR11","doi-asserted-by":"crossref","unstructured":"Yang P, Xu W, Liang X, Yu S, Yi X, Liu M, et al. Dynamic monitoring of minimal residual disease in newly\u2010diagnosed multiple myeloma. Am J Hematol [Internet]. marzo de 2023 [citado 25 de octubre de 2023];98. Disponible en: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26810","DOI":"10.1002\/ajh.26810"},{"key":"1102_CR12","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ajh.25507","volume":"94","author":"R Alonso","year":"2019","unstructured":"Alonso R, Cedena MT, G\u00f3mez\u2010Grande A, R\u00edos R, Moraleda JM, Caba\u00f1as V, et al. Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma. Am J Hematol. 2019;94:853\u201361.","journal-title":"Am J Hematol"},{"key":"1102_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fimmu.2018.00033","volume":"9","author":"KY Ma","year":"2018","unstructured":"Ma KY, He C, Wendel BS, Williams CM, Xiao J, Yang H, et al. Immune repertoire sequencing using molecular identifiers enables accurate clonality discovery and clone size quantification. Front Immunol. 2018;9:33.","journal-title":"Front Immunol"},{"key":"1102_CR14","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3389\/fimmu.2019.00782","volume":"10","author":"NG Van Der Maas","year":"2019","unstructured":"Van Der Maas NG, Berghuis D, Van Der Burg M, Lankester ACB. Cell reconstitution and influencing factors after hematopoietic stem cell transplantation in children. Front Immunol. 2019;10:782.","journal-title":"Front Immunol"},{"key":"1102_CR15","doi-asserted-by":"publisher","first-page":"1123968","DOI":"10.3389\/fimmu.2023.1123968","volume":"14","author":"A Pelissier","year":"2023","unstructured":"Pelissier A, Luo S, Stratigopoulou M, Guikema JEJ, Rodr\u00edguez Mart\u00ednez M. Exploring the impact of clonal definition on B-cell diversity: implications for the analysis of immune repertoires. Front Immunol. 2023;14:1123968.","journal-title":"Front Immunol"},{"key":"1102_CR16","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.3390\/cancers14194628","volume":"14","author":"M Wu","year":"2022","unstructured":"Wu M, Zhang J, Wang Y, Mi L, Wang X, Liu W, et al. The clonal diversity of peripheral B cell receptor immune repertoire impaired by residual malignant b cells predicts treatment efficacy in B cell lymphoma patients. Cancers. 2022;14:4628.","journal-title":"Cancers"},{"key":"1102_CR17","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1002\/ajh.25641","volume":"94","author":"EH Rustad","year":"2019","unstructured":"Rustad EH, Misund K, Bernard E, Coward E, Yellapantula VD, Hultcrantz M, et al. Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma. Am J Hematol. 2019;94:1364\u201373.","journal-title":"Am J Hematol"},{"key":"1102_CR18","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1158\/1078-0432.CCR-21-1059","volume":"27","author":"KC Anderson","year":"2021","unstructured":"Anderson KC, Auclair D, Adam SJ, Agarwal A, Anderson M, Avet-Loiseau H, et al. Minimal residual disease in myeloma: application for clinical care and new drug registration. Clin Cancer Res. 2021;27:5195\u2013212.","journal-title":"Clin Cancer Res"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01102-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01102-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01102-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T09:07:00Z","timestamp":1723021620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01102-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1102"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01102-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4150524\/v1","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"22 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This retrospective study was approved by the UCSF Institutional Review Board (IRB), IRB number 15-17721. The research complies with the Helsinki Declaration. Informed consent has been obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"131"}}